A pilot randomized trial of ketamine for suicidal ideation in a pediatric emergency department
Authors:
- 3 June 2026
- journal article
- Published by Springer Nature in Canadian Journal of Emergency Medicine
- Vol. 28 (9) , 836-844
Abstract
Emergency department (ED) visits by adolescents with suicidal ideation have increased, with no rapid-acting treatments identified for ED use. This pilot study explored the feasibility of a randomized controlled trial of ketamine in the ED for adolescents with suicidal ideation. Three-arm, triple-blinded randomized controlled trial comparing intravenous ketamine (0.5 mg/kg), midazolam (0.03 mg/kg), and saline (0.9%) in adolescents requiring hospitalization for suicidal ideation. We primarily reported recruitment proportion as a measure of feasibility. Secondary outcomes included: additional aspects of feasibility (barriers to enrolment, retention, blinding, and adverse events) and distribution of suicidal ideation scores 90 min post-infusion on questions 3-5 of the Columbia Suicide Severity Rating Scale, item 10 of the Montgomery-Åsberg Depression Rating Scale, and a pragmatic 0-10 Likert scale to estimate future randomized controlled trial sample size. Out of 21 eligible patients and guardians, 15 (71%, 95% CI 48, 87%) agreed to participate when offered the opportunity. Key barriers to enrolment included limited ED resources and absence of a consenting parent at time of assessment. Retention at 7, 14, 21, and 28-days was 93, 86, 73, and 73%. No serious or unexpected adverse events occurred. Blinding appeared reasonably effective. The median [IQR] Columbia Suicide Severity Rating Scale, Montgomery-Åsberg Depression Rating Scale, and pragmatic Likert scale scores at 90 min were 0 [0, 2], 4 [2, 4], 5 [5, 6] for ketamine; 0 [0, 3], 3 [3, 6], 6 [3, 7] for midazolam; and 3 [2, 3], 4 [4, 5], 6 [6, 7] for saline. Despite a small sample, our participation rate was high and trial design appeared feasible and safe. Dedicated research nurses and a mature-minor consent process could address key barriers to enrolment in future trials to determine if ketamine could provide ED physicians with the first rapid-acting pharmacological treatment for acute pediatric suicidal ideation. gov: NCT04955470.Keywords
Funding Information
- BC Children’s Hospital Foundation
This publication has 36 references indexed in Scilit:
- Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled StudyJournal of the American Academy of Child & Adolescent Psychiatry, 2025
- Barriers, Solutions, and Opportunities for Adapting Critical Care Clinical Trials in the COVID-19 PandemicJAMA Network Open, 2024
- Mental Health Hospitalizations in Canadian Children, Adolescents, and Young Adults Over the COVID-19 PandemicJAMA Network Open, 2024
- Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2023
- Trends and Seasonality of Emergency Department Visits and Hospitalizations for Suicidality Among Children and Adolescents in the US from 2016 to 2021JAMA Network Open, 2023
- National Trends in Mental Health–Related Emergency Department Visits Among Youth, 2011-2020JAMA, 2023
- Trends in Pediatric Emergency Department Utilization for Mental Health-Related VisitsThe Journal of Pediatrics, 2015
- Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxietyJournal of Psychiatric Research, 2014
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Sample size calculations for ordered categorical dataStatistics in Medicine, 1993